NATCO Pharma profit and loss

Latest FY26

Revenue: ₹4,078cr−7.9% on FY25
EBITDA: ₹1,437cr−34.6% on FY25
Net profit: ₹1,419cr−24.7% on FY25
EPS: ₹79.20−24.8% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	3,485	4,078	4,430	3,999	2,707	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	295	298	355	128	105
	3,780	4,376	4,784	4,127	2,812
	571	594	536	523	475
	194	203	166	151	176
	−159	−106	−12.5	42.7	−23.7
	698	687	595	525	487
	46.5	36.7	23.9	19.2	14.5
	196	207	235	187	164
	1,130	1,264	949	1,006	658
	2,675	2,885	2,493	2,453	1,950
	1,052	1,437	2,196	1,751	936
	856	1,230	1,961	1,565	772
Profit
	1,105	1,491	2,291	1,674	862
	1,105	1,491	2,291	1,674	862
	237	304	438	317	163
	−146	−185	−29.6	−31.3	−16.1
	90.7	119	408	285	147
	131	46.6	0.0	0.0	0.0
	1,145	1,419	1,883	1,388	715
	1,014	1,372	1,883	1,388	715
	359	287	−24.0	14.9	2.7
	1,504	1,706	1,859	1,403	718
	1,144	1,419	1,885	1,388	715
	0.4	0.0	−2.0	0.0	0.0
Per share
	₹63.89	₹79.20	₹105.26	₹77.34	₹39.18
	₹63.89	₹79.20	₹105.26	₹77.34	₹39.18
Other comprehensive income — detail
	359	287	−24.0	—	—
	44.6	40.3	−3.4	7.6	−21.0
	—	—	—	0.0	−1.6
	315	247	−20.6	7.3	22.1
	1,503	1,706	1,861	1,403	718
	0.4	0.0	−2.0	0.0	0.0
Per share — as-filed variants
	₹63.89	₹79.20	₹105.26	₹77.34	₹39.18
	₹63.89	₹79.20	₹105.26	₹77.34	₹39.18
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	2,880	3,388	3,740	3,282	2,080
	82.6%	83.1%	84.4%	82.1%	76.8%
Adjusted (ex-exceptional items) — derived
	1,105	1,491	2,291	1,674	862
	1,145	1,419	1,883	1,388	715
	₹63.89	₹79.20	₹105.26	₹77.34	₹39.18

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NATCOPHARM₹793.00

NATCO Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDRREDDY ZYDUSLIFE SUNPHARMA LALPATHLAB NEULANDLAB NH SAILIFE COHANCEMcap ₹14,195 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	2,707.1	3,998.8	4,429.5	4,078.3	3,484.6
Other Income	104.6	128.1	354.5	297.6	295.1
Total Income	2,811.7	4,126.9	4,784.0	4,375.9	3,779.7
Expenses
+ Cost of Materials Consumed	475.3	522.5	536.2	593.5	570.7
+ Purchases of Stock-in-Trade	175.7	151.4	166.1	203.2	193.7
+ Changes in Inventories	-23.7	42.7	-12.5	-106.2	-159.4
+ Employee Benefit Expense	486.7	525.0	594.5	687.2	697.5
+ Finance Costs	14.5	19.2	23.9	36.7	46.5
+ Depreciation & Amortisation	163.8	186.8	235.2	206.6	196.1
+ Other Expenses	657.5	1,005.8	949.2	1,264.1	1,130.1
Total Expenses	1,949.8	2,453.4	2,492.6	2,885.1	2,675.2
EBITDA	935.6	1,751.4	2,196.0	1,436.5	1,052.0
EBIT	771.8	1,564.6	1,960.8	1,229.9	855.9
Profit
PBT before Exceptional Items	861.9	1,673.5	2,291.4	1,490.8	1,104.5
Pretax Income	861.9	1,673.5	2,291.4	1,490.8	1,104.5
+ Current Tax	162.7	316.5	437.6	303.5	236.6
+ Deferred Tax	-16.1	-31.3	-29.6	-184.6	-145.9
Tax Expense	146.6	285.2	408.0	118.9	90.7
+ Share of Associates & JVs	0.0	0.0	0.0	46.6	130.9
Net Income	715.3	1,388.3	1,883.4	1,418.5	1,144.7
+ Net Income — Continuing Ops	715.3	1,388.3	1,883.4	1,371.9	1,013.8
+ Other Comprehensive Income	2.7	14.9	-24.0	287.4	359.1
Total Comprehensive Income	718.0	1,403.2	1,859.4	1,705.9	1,503.8
Net Income to Common	715.3	1,388.3	1,885.4	1,418.5	1,144.3
Minority Interest	0.0	0.0	-2.0	0.0	0.4
Per Share
Basic EPS	39.18	77.34	105.26	79.20	63.89
Diluted EPS	39.18	77.34	105.26	79.20	63.89
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-24.0	287.4	359.1
+ Items NOT to be Reclassified to P&L	-21.0	7.6	-3.4	40.3	44.6
+ Tax on Items NOT to be Reclassified — alt tag	-1.6	0.0	—	—	—
+ Items to be Reclassified to P&L	22.1	7.3	-20.6	247.1	314.5
Comprehensive Income — Owners of Parent	718.0	1,403.2	1,861.4	1,705.9	1,503.4
Comprehensive Income — Non-controlling Interests	0.0	0.0	-2.0	0.0	0.4
Per Share — as-filed variants
Basic EPS — Continuing Operations	39.18	77.34	105.26	79.20	63.89
Diluted EPS — Continuing Operations	39.18	77.34	105.26	79.20	63.89
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,079.8	3,282.2	3,739.7	3,387.8	2,879.6
Gross Margin %	76.83	82.08	84.43	83.07	82.64
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	861.9	1,673.5	2,291.4	1,490.8	1,104.5
Net Income Adj (tax-effected)	715.3	1,388.3	1,883.4	1,418.5	1,144.7
EPS Adj	39.18	77.34	105.26	79.20	63.89
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	36.5	35.8	35.8	35.8	35.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.